CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Total revenues	$ 9,027,738	$ 1,931,497
Operating expenses:
Selling, general and administrative	12,610,552	10,031,180
Research and development	3,765,440	3,321,763
Depreciation and amortization	844,438	285,730
Impairment losses	821,741	0
Total operating expenses	18,042,171	13,638,673
LOSS FROM OPERATIONS	(13,113,821)	(12,534,999)
Other (expense) income:
Interest income (expense), net	13,675	(115,830)
Loss on extinguishment of convertible notes payable	(1,774,662)	0
Gain on extinguishment of notes payable	839,945	0
Other expense, net	(243,576)	(378,075)
Loss before provision for income taxes	(14,278,439)	(13,028,904)
Provision for income taxes	0	0
NET LOSS	(14,278,439)	(13,028,904)
Less: Net (income) loss attributable to noncontrolling interest	(8,003)	1,685
NET LOSS attributable to Applied DNA Sciences, Inc.	(14,286,442)	(13,027,219)
Deemed dividend related to warrant modifications		(2,842)
NET LOSS attributable to common stockholders	$ (14,286,442)	$ (13,030,061)
Net loss per share attributable to common stockholders - basic	$ (2.07)	$ (3.32)
Net loss per share attributable to common stockholders - diluted	$ (2.07)	$ (3.32)
Weighted average shares outstanding - basic	6,916,999	3,919,072
Weighted average shares outstanding - diluted	6,916,999	3,919,072
Product revenues
Revenues:
Total revenues	$ 3,295,849	$ 615,430
Cost of revenues	1,496,659	720,900
Service revenues
Revenues:
Total revenues	937,735	1,238,517
Clinical laboratory service revenues
Revenues:
Total revenues	4,794,154	77,550
Cost of revenues	$ 2,602,729	$ 106,923